Nektar Therapeutics
NKTR | NASDAQ
$66.84
-$0.26 (-0.39%)
At close: Sep 21, 2026, 4:00 PM ET
$66.86
+$0.02 (+0.03%)
Pre-market:
Sep 22, 2026, 8:55 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 55.23M | 98.43M | 90.12M | 92.06M | 101.91M | 152.92M |
Cost of Revenue | n/a | 30.69M | 36.64M | 21.64M | 24.9M | 19.48M |
Gross Profit | 55.23M | 67.74M | 53.48M | 70.42M | 77.01M | 133.44M |
Operating Income | -130.77M | -105.2M | -137.43M | -240.24M | -446.1M | -379.92M |
Interest Income | 10.44M | 14.5M | 19.01M | 6.78M | 2.73M | 18.28M |
Pretax Income | -164.21M | -119.2M | -276.26M | -364.98M | -523.28M | -443.95M |
Net Income | -164.08M | -118.96M | -276.06M | -368.2M | -523.84M | -444.44M |
Selling & General & Admin | 68.67M | 76.75M | 77.42M | 92.33M | 122.84M | 104.68M |
Research & Development | 117.33M | 120.91M | 114.16M | 218.32M | 400.27M | 408.68M |
Other Expenses | n/a | -24.72M | -676K | n/a | n/a | n/a |
Operating Expenses | 186M | 172.94M | 190.9M | 310.66M | 523.11M | 513.36M |
Interest Expense | 26.18M | 28.11M | 25.33M | 28.91M | 47.31M | 37.12M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 186M | 203.63M | 227.55M | 332.29M | 548.01M | 532.84M |
Income Tax Expense | -138K | -239K | -200K | 3.22M | 557K | 493K |
Shares Outstanding (Basic) | 16.87M | 13.71M | 12.67M | 12.48M | 12.22M | 11.91M |
Shares Outstanding (Diluted) | 16.87M | 13.71M | 12.67M | 12.48M | 12.22M | 11.91M |
EPS (Basic) | -9.73 | -8.68 | -21.79 | -29.51 | -42.90 | -37.33 |
EPS (Diluted) | -9.73 | -8.68 | -21.79 | -29.51 | -42.90 | -37.33 |
EBITDA | -137M | -86.7M | -243.11M | -323.87M | -461.82M | -394.33M |
EBIT | -138.03M | -91.09M | -250.92M | -336.07M | -475.97M | -406.83M |
Depreciation & Amortization | 1.03M | 4.39M | 7.82M | 12.2M | 14.15M | 12.5M |
Add to Watchlist
Select watchlists to add or remove NKTR